EOLS — Evolus, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1570562 ·
Last close
$6.61
Market Cap
$435.30M
52W High
$7.32
52W Low
$4.19
ADV30
782,611
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 73,137,000 | 48,897,000 | -6,862,000 | -10,674,000 | 220,646,000 | 49,792,000 | 249,427,000 |
| Dec 2025 | 90,300,000 | 59,291,000 | -291,000 | 130,000 | 225,868,000 | 53,826,000 | 248,974,000 |
| Sep 2025 | 68,967,000 | 45,841,000 | -10,164,000 | -15,737,000 | 218,997,000 | 43,523,000 | 247,757,000 |
| Jun 2025 | 69,387,000 | 45,320,000 | -14,124,000 | -17,142,000 | 228,803,000 | 61,738,000 | 247,455,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-36,584,000
Investing CF
$-8,282,000
Financing CF
$26,587,000
CapEx
$-8,282,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.67
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-671,714,000
Inventory
$24,796,000
Receivables
$52,219,000
ST Investments
—
EBIT TTM
$-23,308,000
Pretax Income TTM
$-42,562,000
Interest Exp TTM
$19,254,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$301,791,008
EBITDA
$-23,152,000
Free Cash Flow
$-23,226,376
Enterprise Value
$566,216,064
Total Cash
$49,792,000
Total Debt
$164,903,008
Shares Out
65,854,751
Trailing EPS
$-0.66
Book Value
$-0.44
ROE
—
ROA
-9.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 297,176,000 | -37,600,000 | -51,641,000 | 225,868,000 | 248,974,000 | — | -42,265,000 |
| Dec 2024 | 266,274,000 | -27,235,000 | -50,420,000 | 232,569,000 | 227,047,000 | — | -17,999,000 |
| Dec 2023 | 202,085,000 | -44,976,000 | -61,685,000 | 188,998,000 | 209,687,000 | — | -34,008,000 |
| Dec 2022 | 148,616,000 | -59,575,000 | -74,412,000 | 177,983,000 | 159,484,000 | — | -84,912,000 |
TTM Snapshot
Revenues TTM
$177,504,000
NetIncome TTM
$-67,982,000
OpCashFlow TTM
$0
Assets (Latest)
$232,569,000
Forward EPS
$0.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $436.38M | $6.68 | — |
| SLN | Silence Therapeutics plc | $429.36M | $9.09 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $426.95M | $3.91 | — |
| LRMR | Larimar Therapeutics, Inc. | $444.62M | $4.28 | — |
| HELP | CYBIN INC. | $425.83M | $6.87 | — |
News headlines (Yahoo Finance, 1h cache)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 20:05 · Yahoo
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
2026-07-08 13:00 · Yahoo
3 High-Growth Insider-Owned Companies With Earnings Surging Up To 80%
2026-05-15 11:35 · Yahoo
Evolus, Inc. Q1 2026 Earnings Call Summary
2026-05-05 00:23 · Yahoo
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
2026-05-04 23:30 · Yahoo
Evolus Q1 Earnings Call Highlights
2026-05-04 22:17 · Yahoo
Evolus (EOLS) Q2 2025 Earnings Call Transcript
2026-05-04 20:34 · Yahoo
How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions
2026-04-26 02:09 · Yahoo
April 2026's Leading Growth Stocks With Insider Confidence
2026-04-16 17:36 · Yahoo
Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference
2026-04-16 04:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.